Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 2a clinical trial evaluating FREE001, a ketamine-based combination therapy for the treatment of treatment-resistant depression (FREE001-TRD-201).

Next Previous
Trial Profile

Phase 2a clinical trial evaluating FREE001, a ketamine-based combination therapy for the treatment of treatment-resistant depression (FREE001-TRD-201).

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 01 May 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs FREE-001 (Primary)
  • Indications Depression; Major depressive disorder
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Acronyms FREE001-TRD-201

Most Recent Events

  • 01 May 2024 New trial record
  • 25 Apr 2024 According to Freedom Biosciences media release, the company received IND approval from U.S. Food and Drug Administration (FDA) ,to proceed with its FREE001-TRD-201 study for the treatment of treatment-resistant depression (TRD).The company will initiate its Phase 2a clinical trial in the first half of this year.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top